Author Archives: admin


Stell Cell Research – Stem Cell Cafe

Here at Macleans, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe youll appreciate the clean, white layout as you read our feature articles. But we dont want to force it on you and its completely optional. Click View in Clean Reading Mode on any article if you want to try it out. Once there, you can click Go back to regular view at the top or bottom of the article to return to the regular layout. Scientist Dr. Mark Post poses with samples of in-vitro meat in a laboratory, at the University of Maastricht in the Netherlands on November 9, 2011. (Francois Lenoir/Reuters) Its high time for summer barbecue season. On Aug. 5, as long weekend revelers across Canada throw steaks and sausages on the grill, Dr. Mark Post will be cooking up something very different: a hamburger made of animal stem cells, grown in his lab at Maastricht University in the Netherlands. This one little five-ounce patty has taken him years to perfect, at a cost of 300,000 euros, or over $409,500 (donated by an anonymous investor), making it what must be the most expensive and labour-intensive sandwich patty in history. Some doubted it could be done. As the burger is unveiled in Londonthen bitten, chewed, swallowed and consumed, for all the world to seePosts burger will redefine meat as we know it. This is the food of the future. Post, a medical doctor, has been attempting to create tissues in the lab for almost a decade. The applications are huge: engineered human tissues could be used to test drugs, for example, or to treat many diseases where the body wastes away. To Post, the food application started out as an interesting side project, one that soon stole the spotlight from his other work. Meat for consumption is in theory, much easier to grow, he told Macleans in an interview in 2012. The tissue does not need to physically integrate into the body. I considered it a closer goal to reach, he says, and a very important one. Indeed, the global appetite for meat is growing. Livestock production already takes up 30 per cent of the land surface on our planet, says a 2006 United Nations report, producing more greenhouse gas emissions than all our cars and trucks, combined. According to Patrick O. Brown of Stanford University, eating one four-ounce hamburger is the equivalent of leaving a bathroom faucet running round-the-clock for a week. Developing nations are increasingly emulating the meat-heavy Western diet, and it isnt sustainable. We are heading towards a meat shortage worldwide, Post says. Instead of producing beef, pork and poultry on massive industrial farms, in the near future, he predicts, well be growing it in factories. And while this first hamburger was incredibly expensive to make, as techniques are perfected and lab-grown stem-cell burgers can be mass-produced, the cost will go down; one day it could be lower than the price of traditionally raised meat, which is expected to rise. Of course, growing a minced hamburger pattylet alone a dense, fat-marbled steakisnt a simple task. Post and his team harvested stem cells from a cows muscle tissue, and bathed them in a special formula of nutrients. As these cells start to differentiate into muscle cells, theyre hooked to attachment points (Post has used Velcro) to create tiny strips of tissue, like a tendon. Eventually, they start to contract on their own. The downside for animal lovers is that you still need animals, a donor herd to provide stem cells, Post says. But compared to factory farming today, the number would be very small. If we grew all our meat in a lab, Post believes, the number of livestock worldwide could be reduced by a factor of one millionthe equivalent of reducing 10 billion livestock animals on the planet to 10,000. This would free up land, water, and other resources, while making sure remaining livestock didnt suffer a death fraught with the issues of large-scale slaughter. Other than Post, only a handful of scientists are working on lab-grown meat; others believe the future lies in plant-based substitutes, ones so good they could fool even the most discerning palate, although Post maintains that we humans will always have an appetite for the real thing. Worldwide, the meat-eater population is going to grow. Theres no doubt about that, he says. Posts hamburger is a powerful proof of concept, an important first step. As we begin to unravel the implications of this one burgerfor science, for health care, and for the food supply that feeds everyone on the planetwell be watching on Aug. 5, with bated breath, wondering what, exactly, it tastes like. Anyone who wants to follow along can watch a livestream of the burger consumption on Aug. 5 atculturedbeef.net. Continued here: One lab-grown hamburger, coming up Blog Central, Kate Lunau

Original post:
Stell Cell Research – Stem Cell Cafe

Tackling Huntington’s disease with stem cell therapy in mice

The neurodegenerative disorder Huntingtons disease (HD) is characterised by diminished muscle coordination, cognitive impairment and behavioural changes. It is a genetic disorder caused by the expansion of a CAG trinucleotide repeat in the gene encoding the huntingtin protein. This results in the degeneration of nerve cells, starting with those in the striatum of the brain. At present there is no treatment for this disease, nor any means to slow down its progression. Current therapies therefore focus on managing symptoms. Research is underway to determine whether stem cell therapies could reduce the neuropathological deficits brought on by HD and in doing so slow disease progression. A recent study published in Stem Cell Research & Therapy by Gary Dunbar from Central Michigan University, USA and colleagues, probes the potential of mesenchymal stem cells in treating a mouse model of HD.

Immunohistochemical analysis of low passage (left) and high passage (right) umbilical cord mesenchymal stem cells (blue) transplanted into the striata of R6/2 mice. Stained for NeuN (red) and GFAP (green). Image source: Fink et al, Stem Cell Research & Therapy, 2013, 4:130

Dunbar and colleagues used the R6/2 mouse model of HD to test the efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs). R6/2 mice express the N-terminal portion of the human huntingtin gene, containing a highly expanded CAG repeat, and consequently develop progressive neurological phenotypes resembling the disease in humans. At five weeks of age, R6/2 mice were transplanted with either low passage or high passage UC-MSCs, and were followed for six weeks. The mice underwent a number of behavioural tests, including the rotarod task to assess balance, the Morris water maze and the limb-clasping response. They were subsequently sacrificed for histological analysis. Wild-type and sham-operated R6/2 mice served as the controls.

R6/2 mice treated with high passage UC-MSCs performed better on the rotarod task compared with untreated R6/2 mice at ten weeks of age, although the improvement was transient. The most promising effects of treatment with high passage UC-MSCs were seen in the reduction of neuropathological deficits. The researchers found that untreated R6/2 mice had significantly smaller brain areas than wild-type animals, suggesting brain atrophy. This effect was mitigated in mice treated with high passage UC-MSCs, which showed no difference from wild-type mice in measures of brain area. Transplantation of high passage UC-MSCs into R6/2 mice also preserved substantially more metabolic activity in striatal brain tissue compared with untreated animals.

Although no long-term effects on behaviour were observed in this study, the fact that UC-MSCs significantly reduced neuropathological deficits suggests that stem cells could have therapeutic value in the management of HD.

Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis

Excerpt from:
Tackling Huntington’s disease with stem cell therapy in mice

Alpha Stem Cell Clinics | California’s Stem Cell Agency

RFA 13-06 is one of two RFAs released as part of the CIRM Alpha Stem Cell Clinics (CASC) Network Initiative. The overall goal of the initiative is to accelerate therapeutic development and delivery of stem cell therapies by providing a high-quality, efficient infrastructure to support clinical research emanating from CIRMs funding pipeline as well as non-CIRM funded investigator- or industry-sponsored trials.

The CASC Initiative consists of two linked Requests for Applications (RFAs) that will be co-released:

The Alpha Stem Cell Clinics will provide critical operational support for the conduct of clinical trials for investigational stem cell therapies and will operate as a center of excellence for approved stem cell therapies. They will provide focused resources and expertise in clinical research with novel stem cell-based products, and an array of critical clinical operations support and patient care coordination personnel and resources. These activities would be integrated into the larger CASC network, utilizing efficient and standardized methods to accomplish its goals and activities.

Please see the RFA for full details. RFA 13-06: CIRM Alpha Stem Cell Clinics Awards [pdf]

Informational Webinar CIRM conducted a webinar for prospective applicants on Tuesday, November 5, 2013 to address questions about both RFA 13-06 and 13-07 and the application process. Click the following links for a recording of the webinar and supplemental materials:

Further reading: Appendix A Alpha Stem Cell Clinics Concept Statement [pdf] Appendix B Alpha Stem Cell Clinics: Delivering a New Kind of Medicine [pdf] Appendix C The Alpha Stem Cell Clinic: A Model for Evaluating and Delivering Stem Cell-Based Therapies [pdf]

Submission of an application for a CIRM Alpha Stem Cell Clinics Awards involves a two-step process. A Program Director may only submit one LOI for this RFA and only one LOI will be accepted from each Institution. In addition to the Authorized Organizational Official (AOO) authorization, each LOI must be signed by an Authorized Executive Officer (AEO) who is an organizational official (e.g. Vice-Chancellor, Dean, etc.) with the authority, to nominate the institutions sole candidate for this award. An eligible applicant must first submit a Letter of Intent (LOI) to CIRM following the instructions below. In the second step of the process, eligible applicants will submit a full application.

The Letter of Intent (LOI) must be submitted via the CIRM Grants Management Portal, as follows:

The LOI must be received by CIRM no later than 5:00 pm (PST) on December 16, 2013 via the CIRM Grants Management Portal. No exceptions to this deadline will be made.

Visit link:
Alpha Stem Cell Clinics | California's Stem Cell Agency

www.CLINICell.com "MENISCUS TEAR alternative with PRP and Stem Cell Therapy" – Video


http://www.CLINICell.com "MENISCUS TEAR alternative with PRP and Stem Cell Therapy"
http://www.CLINICell.com offers the latest alternative treatments with PRP and Stem Cell Therapy for an MENISCUS Tear. Platelet Rich Plasma and Stem Cell treatments can be used as an alternative...

By: ClinicellTech

Read the original post:
http://www.CLINICell.com "MENISCUS TEAR alternative with PRP and Stem Cell Therapy" - Video

Stem Cell Treatment and Stem Cell Therapy | Vista Stem Cell

Stem Cell Treatment at Your Fingertips Stem cell therapy has come a long way over the last ten years, despite repeated interventions by some western governments to restrict its research. One place which has not suffered from these setbacks is China.

At our facilities in Beijing, we have been administering treatments using fetal stem cells for nearly ten years with ever improving results. Our sophisticated stem cell treatment techniques and experience ensure patients receive the highest quality therapy in the world and an alternative to existing treatments that they cannot find in their own country.

We use the strictest protocols to ensure that all our stem cells are disease-free and healthy. Most of our doctors were educated in the West and have a strong understanding of the demands of western patients.

We believe people should not have to put up with their illness when an alternative already exists. Our mission is to improve the quality of life of all our patients and enable you to gain control over your life.

View our Current Treatments section to find out more about the stem cell treatment and therapy we can provide you with.

See original here:
Stem Cell Treatment and Stem Cell Therapy | Vista Stem Cell

Cell Therapy News – Shopping cheap jerseys on our online cheap …

Project A.L.S. Announces Research Effort with Lilly Project A.L.S. announced an agreement with Eli Lilly and Company aimed at helping to accelerate the development of potential therapies for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. [Project A.L.S.] Press Release

Life Stem Genetics Announces Collaborative Agreement with American CryoStem Life Stem Genetics, Inc. announced a strategic collaborative agreement with American CryoStem Corporation (CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries. [Business Wire] Press Release

Actinium Pharmaceuticals Announces Plans for Iomab-B Phase III Pivotal Trial Following Meeting with FDA Actinium Pharmaceuticals, Inc. a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer discussed recent progress and outline development plans for the company's clinical stage products: Iomab-B and Actimab-A. [Actinium Pharmaceuticals, Inc.] Press Release

Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) Alnylam Pharmaceuticals, Inc. announced that it has earned a $7 million milestone from its partner Genzyme, a Sanofi company, for achieving Phase II success with patisiran (ALN-TTR02). [Alnylam Pharmaceuticals] Press Release

ARMO BioSciences Initiates Phase I Clinical Trial of First-in-Class Cancer Immunotherapy ARMO BioSciences, Inc. announced that it initiated the first cohort of patients with advanced solid tumors in a Phase I clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10. [PR Newswire Association LLC] Press Release

Alliqua Receives License to Celgene Cellular Therapeutics Advanced Wound Care ProductsAlliqua, Inc. entered into a licensing agreement with Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation, whereby Alliqua received the right to develop and market the advanced wound care products Biovance and Extracellular Matrix. [Alliqua Inc.] Press Release

Leading Scientists Join BioResearch Open Access Editorial Board under Editor-in-Chief Robert Lanza Dr. Robert Lanza announced that in addition to the distinguished group of Section Editors, including Alan Russell, James Wilson, and Sir Ian Wilmut, among others, fifteen world renowned experts have joined the new Editorial Board of BioResearch Open Access, including ten members of the National Academy of Sciences and Institute of Medicine. [Mary Ann Liebert, Inc.] Press Release

Allergen Research Corporation Announces $17 Million Series A Financing Allergen Research Corporation announced the successful completion of financing to support its upcoming Phase IIb clinical trial to evaluate peanut allergy oral immunotherapy with characterized peanut allergen, as well as related development projects. [Allergen Research Corporation] Press Release

Regeneus to Fast-Track Human Cells under New Japanese Laws The Japanese parliament has passed new laws that provide a rapid approval process specifically designed for human stem cell therapies. Regenerative medicine company, Regeneus, is ready to move on the opportunity. These new laws give the company a unique opportunity to fast-track the clinical trial and potential approval of its new human off-the-shelf cell therapy to treat osteoarthritis and other inflammatory musculoskeletal conditions into the Japanese market. [Regeneus Ltd.] Press Release

New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products Regenerative medicine company Mesoblast Limited gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market. [Mesoblast Limited] Press Release

Follow this link:
Cell Therapy News - Shopping cheap jerseys on our online cheap ...

The Doctors: Lichen Sclerosus Symptoms & Stem Cell Therapy …

The Doctors: Lichen Sclerosus Symptoms

The Doctors continued their womens health discussion with Jayme, a woman who felt hopeless after a debilitating vaginal condition left her unable to live a normal life. Hear how The Doctors were finally able to offer help.

After Jayme welcomed a son with her husband, Brian, she experienced burning and itching that her OB/GYN diagnosed as a yeast infection. In fact, Jayme had Lichen Sclerosus, and was devastated to learn that there was no cure, and hardly any treatment available.

Jayme said that her condition caused white patches, severe itching, and razor-blade type pain while urinating. Even sitting on a hard chair would feel like intense menstrual cramp pain. Clearly, this condition affected not just Jaymes personal life, but also her everyday life.

The Doctors discussed how Jaymes painful lichen sclerosus, developed after childbirth, was treated with stem cell therapy.

Dr. Jennifer Ashton said that 1 in 60 women will develop Lichen Sclerosus, but its often misdiagnosed, which can make treating the condition extremely difficult.

Stem cell therapist Dr. Nathan Newman volunteered to offer Jayme a new treatment. Using mini-liposuction and PRP (platelet rich plasma), Dr. Newman gave Jayme three sessions over a period of nine months. Amazingly, Jayme started feeling better after her second treatment, and is now feeling great.

Lichen Sclerosus is also an auto-immune issue, so not surprisingly, Jayme was also diagnosed with a thyroid condition. If youre worried about Lichen Sclerosus, Dr. Ashton recommends using a mirror to examine yourself. Lichen looks like white tissue paper with a wrinkly texture. Also look for unusual moles, spots, or bumps. If you notice anything strange, its best to visit your doctor as soon as possible.

Tagged as: Lichen Sclerosus, Lichen Sclerosus Jayme, Lichen Sclerosus Stem Cell Therapy, Lichen Sclerosus Symptoms, Lichen Sclerosus Treatment, The Doctors Lichen Sclerosus

Read this article:
The Doctors: Lichen Sclerosus Symptoms & Stem Cell Therapy ...

UCLA stem cell research may lead to improved prostate cancer …

Researchers at UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have made another breakthrough in the fight against prostate cancer. They found that two types of malignant prostate cancer cells can develop in one type of stem cell; thus, making prostate cancer stem cells a moving target for treatments. The researchers note that the finding could lead to new and improved treatments that can target prostate cancer cells. They published their findings online on November 26 in the Proceedings of the National Academy of Sciences.

Adult stem cells are regenerative cells that replace diseased or damaged cells in organs. The researchers previously reported that prostate cancer can originate in basal type stem cells. The new study, based on that research, showed that tumors can start in basal stem cells that evolve to luminal cells that result in aggressive spread of the cancer and that these luminal cells can change in their characteristics over time; thus, making them resistant to treatment.

Study author Dr. Andrew Goldstein explained, People have begun to think about cancers as being driven by stem cells in the same way that many of our adult organs are maintained by dedicated stem cells. Based on this new understanding, a lot of excitement surrounds the concept of going right to the root of the tumor and targeting those stem cells to eradicate the cancer.

Patients with aggressive prostate cancer are often treated with anti-androgen (anti-male hormone) therapy; the basal stem cells that develop into the cancer cells look different from the luminal cells that maintain the aggressive disease. In addition, the tumor stem cells that are not destroyed by the anti-androgen treatment look different from the previous two. Because of this process, in order to develop an appropriate treatment, the researchers must identify cell types that evolve as the disease and its treatment develop. Now that the researchers have determined that prostate cancer stem cells can change what their appearance, he investigators are now searching for possible elements that are consistent within the stem cells and do not change through stem cell evolution. They are of the opinion that this knowledge will help develop drugs that target the evolving cancer stem cells. Thus , they are now attempting to detect some of the factors that define a stem cell regardless of its external appearance. They stress that it is extremely important to understand the continual evolution of the stem cells physical appearance, particularly as tumors adapt to become resistant to new and more potent therapies.

Here is the original post:
UCLA stem cell research may lead to improved prostate cancer ...

Stem Cell Therapy || Patient Treatment Disclaimer || Stem Cell …

Click the YES button at the bottom of this page to continue.

This website http://www.cellmedicine.com offers patients, doctors and scientists the opportunity to connect to licensed doctors who use adult stem cells as part of their clinical practice outside of the United States and Canada. Because stem cell therapy is not the standard of care in the US or Canada, the following important disclosures are made:

1) The Stem Cell Institute is not conducting free clinical trials at this time. 2) Health insurance will not cover the treatment fees. 3) The Stem Cell Institute does not provide itemized bills.

Treatments include from 3 to 16 separate stem cell infusions/injections over the course of 4 to 30 days depending upon the protocol employed. A fee will be quoted once your treatment protocol has been determined.

We do not treat ALS, Alzheimers, muscular dystrophy or stroke.

JavaScript is disabled! Please enable JavaScript and then reload this form before you begin. If you cannot do this on your own, please call 1-800-980-STEM and we will arrange for someone to email an application to you. Thank you.

To access the application you must first agree that you have read and understand all of the statements above.

I have read and understand all of the statements above:

Read the original:
Stem Cell Therapy || Patient Treatment Disclaimer || Stem Cell ...

ICMS International Cell Medicine Society

T he International Cellular Medicine Society (ICMS) is an international non-profit dedicated to patient safety through strict evaluation of protocols and rigorous oversight of clinics and facilities engaged in the translation of point-of-care cell-based treatments.As a Professional Medical Association, the ICMS represents Physiciansand Researchersfrom over 35 countries who share a mission to provide Scientifically Credible and Medically Appropriate Treatments to Informed Patients.Join the ICMS.

The ICMS Works Tirelessly for the Clincial Translation of Field of Cell-Based Point-of-Care Treatments through:

Comprehensive Medical Standards and Best Practice Guidelines for Cell Based Medicine,

Strict Evaluation and Rigerous Oversight of Stem Cell Clinics and Facilities through aGlobal Accreditation Process,

Physician Education through daily updates on the latest Research on Stem Cells, the monthly Currents In Stem Cell Medicine and the annual International Congress for Regenerative and Stem Cell Medicine.

Join the ICMSto receive the latest news and research from cell-based medicne, including the bi-monthly publication, Currents in Stem Cell Medicine.

Continued here:
ICMS International Cell Medicine Society